From mucosal activity to medicinal products: translational evidence for Akkermansia muciniphila extracellular vesicles
Open Access
- 26 October 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1942618
Abstract
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.Keywords
This publication has 88 references indexed in Scilit:
- Amuc_1473 Links Gut Microbes to Skeletal Homeostasis and Counteracts Multifactorial OsteoporosisAdvanced Science, 2026
- Local administration of polymyxin B-conjugated Akkermansia muciniphila outer membrane vesicles attenuate asthma by suppressing M2 macrophage polarizationScience China Life Sciences, 2026
- Akkermansia Muciniphila‐Inspired Oral siRNA Delivery by Active Matrix‐Penetration and Intracellular Endoplasmic Reticulum AccumulationAdvanced Materials, 2025
- Zonated Copper‐Driven Breast Cancer Progression Countered by a Copper‐Depleting Nanoagent for Immune and Metabolic ReprogrammingAdvanced Science, 2025
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- The inhibitory effects of live and UV-killed Akkermansia muciniphila and its derivatives on cytotoxicity and inflammatory response induced by Clostridioides difficile RT001 in vitroInternational Microbiology, 2023
- Extracellular vesicles derived from Akkermansia muciniphila promote placentation and mitigate preeclampsia in a mouse modelJournal of Extracellular Vesicles, 2023
- Microbiota‐derived extracellular vesicles in interkingdom communication in the gutJournal of Extracellular Vesicles, 2021
- Effect of Akkermansia muciniphila, Faecalibacterium prausnitzii, and Their Extracellular Vesicles on the Serotonin System in Intestinal Epithelial CellsProbiotics and Antimicrobial Proteins, 2021
- Extracellular Vesicles from Child Gut Microbiota Enter into Bone to Preserve Bone Mass and StrengthAdvanced Science, 2021